LetterLetter
Open Access

A foundation model-enhanced CT radiomics signature for the noninvasive assessment of tertiary lymphoid structures and prediction of therapy benefit in gastric cancer

Xianchun Gao, Zhe Li, Jun Yu, Jiangpeng Wei, Didi Wen, Ning Han, Linbin Lu, Yongxi Song, Qiong Xiao, Guangtao Wu, Kun Feng, Shibo Wang, Zhongyang Zhang, Dai Zhang, Ling Chen, Zengshan Li, Minwen Zheng, Yong Xia and Yongzhan Nie
Cancer Biology & Medicine April 2026, 20260076; DOI: https://doi.org/10.20892/j.issn.2095-3941.2026.0076

References

  1. 1.↵
    2. Sundar R,
    3. Nakayama I,
    4. Markar SR,
    5. Shitara K,
    6. van Laarhoven HWM,
    7. Janjigian YY, et al.
    Gastric cancer. Lancet. 2025; 405: 2087–102.
    OpenUrlCrossRefPubMed
  2. 2.
    2. Verschoor YL,
    3. van de Haar J,
    4. van den Berg JG,
    5. van Sandick JW,
    6. Kodach LL,
    7. van Dieren JM, et al.
    Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial. Nat Med. 2024; 30: 519–30.
    OpenUrlPubMed
  3. 3.↵
    2. Chong X,
    3. Madeti Y,
    4. Cai J,
    5. Li W,
    6. Cong L,
    7. Lu J, et al.
    Recent developments in immunotherapy for gastrointestinal tract cancers. J Hematol Oncol. 2024; 17: 65.
    OpenUrlPubMed
  4. 4.↵
    2. Vanhersecke L,
    3. Brunet M,
    4. Guegan JP,
    5. Rey C,
    6. Bougouin A,
    7. Cousin S, et al.
    Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021; 2: 794–802.
    OpenUrlPubMed
  5. 5.
    2. Li Z,
    3. Jiang Y,
    4. Li B,
    5. Han Z,
    6. Shen J,
    7. Xia Y, et al.
    Development and validation of a machine learning model for detection and classification of tertiary lymphoid structures in gastrointestinal cancers. JAMA Netw Open. 2023; 6: e2252553.
  6. 6.↵
    2. Deng S,
    3. Chen Y,
    4. Song B,
    5. Wang H,
    6. Huang S,
    7. Wu K, et al.
    Tertiary lymphoid structures in cancer: spatiotemporal heterogeneity, immune orchestration, and translational opportunities. J Hematol Oncol. 2025; 18: 97.
    OpenUrlPubMed
  7. 7.↵
    2. Chen Y,
    3. Sun Z,
    4. Yin J,
    5. Ahmad MU,
    6. Zhou Z,
    7. Feng W, et al.
    Digital assessment of tertiary lymphoid structures and therapeutic responses in gastric cancer: a multicentric retrospective study. Int J Surg. 2024; 110: 6732–47.
    OpenUrlPubMed
  8. 8.↵
    2. Niu C,
    3. Lyu Q,
    4. Carothers CD,
    5. Kaviani P,
    6. Tan J,
    7. Yan P, et al.
    Medical multimodal multitask foundation model for lung cancer screening. Nat Commun. 2025; 16: 1523.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Pai S,
    3. Bontempi D,
    4. Hadzic I,
    5. Prudente V,
    6. Sokac M,
    7. Chaunzwa TL, et al.
    Foundation model for cancer imaging biomarkers. Nat Mach Intell. 2024; 6: 354–67.
    OpenUrlPubMed
  10. 10.↵
    2. Su JY,
    3. Li JR,
    4. Pan LX,
    5. Ma YL,
    6. Tian W,
    7. Jiang YM, et al.
    Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy. Hepatology. 2025.
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section